Autres langues Corbus Pharmaceuticals Holdings, Inc.

Actions

CRBP

US21833P3010

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 16:57:37 08/10/2026			Varia. 5j.	Varia. 1 janv.
5,220 ^USD	-4,92%		-16,25%	-34,77%

29/09	Corbus Pharmaceuticals Holdings, Inc. annonce l’administration du traitement au premier patient dans l’étude d’enregistrement TEMPO-1 de CRB-701 chez des patients atteints d’un cancer oropharyngé en 2e ligne et au-delà	CI
14/09	Transcript : Corbus Pharmaceuticals Holdings, Inc. - Special Call

Autres langues

29/09	Corbus Pharmaceuticals Holdings, Inc. Announces First Patient Dosed in Tempo-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
29/09	Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
14/09	Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
14/09	Corbus Pharma Reports Positive Top-Line Data From Weight-Loss Drug Study
14/09	Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
14/09	Corbus Pharmaceuticals Reports Positive Topline Data From CANYON-1 Study Of Daily Oral CRB-913 For Obesity Treatment
11/09	Corbus Pharmaceuticals Holdings Hosts Conference Call to Discuss Topline Data from Canyon-1 Clinical Trial and the Potential of Crb-913 in Obesity
11/09	Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
18/08	Corbus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
17/08	Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/08	Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Corbus Pharmaceuticals: Q2 Earnings Snapshot
06/08	Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
04/08	Corbus Pharmaceuticals Announces Last Patient Last Visit In Canyon-1 Study Of CRB-913 For The Treatment Of Obesity
04/08	Corbus Pharmaceuticals Completes Patient Visits in Phase 1b Obesity Study
04/08	Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
30/07	CSPC-Licensed Oropharyngeal Cancer Drug Cleared for U.S. Registrational Trial
28/07	Corbus Pharmaceuticals Announces FDA Clearance to Initiate Tempo-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
28/07	Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
06/07	Corbus Pharmaceuticals Holdings, Inc. Announces Appointment of Leonardo Viana Nicacio as Chief Medical Officer
06/07	Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
29/06	Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2000 Index
29/06	Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2000 Value Benchmark
29/06	Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 3000E Index
29/06	Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 3000E Value Benchmark